Shanghai Pharma to pay dividend, overhaul governance with audit committee

Shanghai Pharmaceuticals Holding Co. announced an interim cash dividend of RMB1.2 per 10 shares for the six months ended June 30, 2025, pending shareholder approval on December 9, 2025. This distribution, totaling RMB445,003,417.08, represents 9.98% of the consolidated net profit attributable to shareholders for the period. The company's total share capital as of June 30, 2025, is 3,708,361,809 shares.

The dividend announcement follows proposed amendments to the company's Articles of Association and Implementation Rules of Cumulative Voting System, driven by revisions in the Company Law of the People’s Republic of China and other regulatory guidelines. Key changes include the abolishment of the supervisory board, replaced by an audit committee, and adjustments to shareholder meeting procedures and director qualifications.

The company will hold an Extraordinary General Meeting on December 9, 2025, to approve these changes and the interim profit distribution plan. These reforms aim to enhance corporate governance and ensure full exercise of shareholder rights.